[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"postherpetic-neuralgia--phn-\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:postherpetic-neuralgia--phn-":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,40,69,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100636450","intradermal-exosomes-platelet-rich-plasma-and-steroids-for-post-herpetic-neuralgia-100636450",false,"NCT07565844","Intradermal Exosomes, Platelet-Rich Plasma, and Steroids for Post-Herpetic Neuralgia","A Comparative Study of Intradermal Injection of Exosomes, Platelet-Rich Plasma and Steroids in the Treatment of Post-Herpetic Neuralgia","Inclusion Criteria:\n\n* Patients with post-herpes zoster persistent dermatomal pain consistent with post-herpetic neuralgia for at least 90 days.\n\nMale or female patients. Age 18 years or older. Willingness to comply with study procedures and attend follow-up visits. Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n* History of hypersensitivity to any of the study treatments. Pregnancy. Any type of skin infection involving the affected dermatome. Immunocompromised patients, including patients with cancer or HIV. Patients with bone marrow aplasia. Patients with known bleeding tendency, platelet dysfunction, or thrombocytopenia, defined as platelet count less than 150 × 10⁹\u002FL.\n\nRegular use of anticoagulant or antiplatelet drugs.","ALL","18 Years",{"count":19,"type":20},45,"ESTIMATED","INTERVENTIONAL",[23],"NA","This randomized controlled clinical trial will evaluate and compare the efficacy and safety of intradermal injection of exosomes, platelet-rich plasma, and corticosteroid in patients with post-herpetic neuralgia. Forty-five adult patients with dermatomal pain persisting for at least 90 days after herpes zoster will be enrolled from outpatient clinics. Participants will be assigned to one of three groups: intradermal exosome injection, intradermal autologous platelet-rich plasma injection, or intradermal triamcinolone acetonide injection. Each group will receive four treatment sessions every two weeks. Outcomes will include pain severity, neuropathic pain characteristics, quality of life, patient satisfaction, and adverse effects, assessed at baseline, at the final session, and during follow-up visits at 3 and 6 months after the last session.",[26],"Postherpetic Neuralgia ( PHN )","RECRUITING","2026-04-27",{"date":30,"type":31},"2026-05-04","ACTUAL",{"date":33,"type":31},"2025-02-02",{"date":35,"type":20},"2026-11-11",{"name":37,"class":38},"Zagazig University","OTHER_GOV",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":51,"conditions":52,"keywords":53,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":39},"100592240","electroacupuncture-for-phn-efficacy-and-biomarker-evaluation-in-a-multicenter-randomized-sham-controlled-trial-protocol-100592240","NCT06990854","Electroacupuncture for PHN: Efficacy and Biomarker Evaluation in a Multicenter, Randomized, Sham-Controlled Trial Protocol","Inclusion Criteria:\n\n* Meet the diagnostic criteria for PHN;\n* Age between 20 and 80 years old;\n* Voluntarily participate in the trial and sign the informed consent form.\n\nExclusion Criteria:\n\n* Pregnant or lactating women;\n* Presence of severe liver or kidney dysfunction, malignant tumors, or other serious diseases;\n* Presence of hematologic diseases or coagulation disorders;\n* Presence of mental illness or other cognitive impairments, unable to understand or unwilling to cooperate with the study requirements.","20 Years","80 Years",{"count":49,"type":20},207,[23],"The investigators are conducting a clinical study with the following objectives: to evaluate the clinical efficacy of electroacupuncture combined with pregabalin in treating Postherpetic Neuralgia(PHN); to investigate the correlation between serum biomarker levels and pain symptoms;and to determine whether serum biomarkers can serve as prognostic indicators for PHN.\n\nThis study utilizes a randomized controlled trial design with assessor blinding. A total of 207 eligible PHN patients were randomly assigned to three groups in a 1:1:1 ratio: the electroacupuncture group, the pharmacotherapy group, and the sham acupuncture group. Comparative analyses of pain intensity and serum biomarker concentrations were conducted across these groups.\n\nFor the assessment of clinical outcomes, the investigators employed the following measures: the Numerical Rating Scale(NRS), the Hamilton Anxiety Scale(HAMA), the Hamilton Depression Scale(HAMD), the 36-Item Short Form Health Survey(SF-36), serum levels of substance P(SP)and Neuropeptide Y(NPY), and inflammatory markers(IL-10,TNF-α). These assessments were performed at baseline and at the end of weeks 1, 2, 3, and 4 of treatment.\n\nThe investigators anticipate that this clinical trial will enhance our understanding of the therapeutic efficacy and underlying mechanisms of acupuncture in managing PHN. It aims to elucidate the relationship between serum biomarkers and the clinical manifestations of PHN, as well as to explore their potential prognostic value in disease outcomes.",[26],[54,55,56,57,58],"acupuncture","Postherpetic Neuralgia","serum biomarkers","serum substance P","Neuropeptide Y","NOT_YET_RECRUITING","2025-07-02",{"date":62,"type":31},"2025-07-09",{"date":64,"type":20},"2025-07-01",{"date":66,"type":20},"2026-12",{"name":68,"class":38},"Dexiong Han",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":16,"minAge":77,"maxAge":47,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":91,"leadSponsor":93,"locationsCount":4},"100595919","early-screening-markers-of-herpes-zoster-neuralgia-100595919","NCT07038707","Early Screening Markers of Herpes Zoster Neuralgia","Research on the Identification of Early Screening Markers for Herpes Zoster Neuralgia Based on Intestinal Flora Analysis","Inclusion Criteria:\n\n* The definite diagnoses were PHN (disease course ≤ 1 month), PHN (1 month \\\u003C disease course \\\u003C 2 months), and PHN (disease course \\> 3 months); Age equal to 50 years old; Not accompanied by other chronic pain diseases; Sign the informed consent form.\n\nExclusion Criteria:\n\n* There are underlying digestive system diseases such as irritable bowel syndrome and inflammatory bowel disease; There are obvious gastrointestinal discomfort symptoms such as diarrhea and abdominal distension; There is immunosuppression or autoimmune disease; Antibiotics, acid suppressants or drugs that interfere with the intestinal flora have been used within the past month; Have a history of mental illness or abuse of tobacco and alcohol (2 packs per day)",true,"50 Years",{"count":79,"type":20},150,"OBSERVATIONAL","Herpes zoster (HZ), especially postherpetic neuralgia, is one of the most typical types of clinical neuralgia. The incidence rate of HZ in China is approximately 7.7%. Among them, 29.8% of HZ patients eventually develop PHN. About 20% of PHN patients suffer from severe neuralgia for more than one year, or even ten years. It is worth noting that patients with neuralgia are prone to comorbidities such as depression, anxiety and sleep disorders, which seriously affect their work efficiency and quality of life. This is a great torment to both the patients and their families, and it also imposes a heavy burden on the medical system.\n\nProfessor Xiao Lizu, a collaborator of our team, has discovered in clinical practice that spinal cord electrical stimulation for HZ patients can significantly reduce the risk of developing PHN. Other therapies for reducing the risk of PHN include multiple parvertebral injections of local anesthetics\u002Fsteroids, which require patients to return for repeated visits. Although these intervention measures have good effects, they may bring additional economic burdens to patients, treatment side effects and prolong their hospital stays. Therefore, they are not suitable for all patients. From this perspective, our development of early screening methods and selective non-pharmacological intervention only for high-risk patients will improve the overall treatment status of HZ, effectively reduce the incidence of PHN, and alleviate the burden on medical insurance and the medical system at the same time.\n\nThis project aims to conduct the following research by analyzing the intestinal flora of patients: identifying biomarkers with the ability to predict the risk of PHN in patients, constructing a machine learning classifier for risk prediction, and developing an early screening kit based on this.\n\nFurthermore, traditional studies mostly focus on a single pathological link and lack systematic multi-dimensional analysis. In recent years, the cerebral lymphatic system, as a key pathway for the clearance of metabolic wastes in the brain, has attracted widespread attention. Furthermore, the role of the gut-brain axis in pain regulation has gradually been recognized. Therefore, it is of great scientific significance to integrate and explore the pathological mechanism of PHN from three dimensions: the lymphatic system, neuroinflammation, and intestinal flora.\n\nThis project assumes that patients with PHN have a pathological triad of \"lymphoid dysfunction - neuroinflammatory activation - intestinal flora imbalance\". The specific manifestations are as follows: Impaired lymphoid clearance function (decreased DTI-ALPS index and increased free water), activated systemic inflammatory response (elevated TNF-α and IL-6), and disordered intestinal flora structure (decreased α diversity and increased opportunistic pathogenic bacteria). The three interact with each other and have a synergistic effect, jointly participating in the pathogenesis of PHN.The expected outcome of this project may provide new options for pain management of the large group of neuralgia patients, improve their quality of life, and has great practicality and practical value.",[26,83],"Lymphatic System Disorder",[85,86,83,26],"Intestinal flora","Inflammation","2025-06-18",{"date":89,"type":31},"2025-06-26",{"date":64,"type":20},{"date":92,"type":20},"2026-12-31",{"name":94,"class":95},"Tongji Hospital","OTHER",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":21,"phases":105,"briefSummary":106,"conditions":107,"keywords":108,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":4},"100584731","effectiveness-of-warm-acupuncture-in-patients-with-postherpetic-neuralgia-100584731","NCT06893172","Effectiveness of Warm Acupuncture in Patients with Postherpetic Neuralgia","Effectiveness of Warm Acupuncture for Postherpetic Neuralgia in the Context of the Qi Stagnation and Blood Stasis Syndrome: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Individuals with a history of herpes zoster in the trunk area.\n* Individuals diagnosed with Postherpetic neuralgia (PHN) by a dermatologist, based on PHN diagnostic criteria, with pain persisting for 3 months or more after the skin lesions have healed.\n* Individuals with a pain intensity score of ≥ 3, assessed using the Visual Analog Scale (VAS).\n* Individuals diagnosed with Qi Stagnation and Blood Stasis syndrome by a Traditional Medicine doctor.\n* Individuals aged 18 years or older.\n* Individuals who volunteer to participate in the study and sign a consent form.\n\nExclusion Criteria:\n\n* Active herpes zoster lesions, confirmed by the dermatologist treating the patient.\n* Pregnant or breastfeeding women.\n* Patients with severe cognitive impairment who cannot understand the study protocol.\n* Patients with a history of allergy to Gabapentin.\n* Currently participating in another interventional study.",{"count":104,"type":20},36,[23],"Postherpetic neuralgia (PHN) is the most common clinical complication of herpes zoster. PHN can persist for months to years, and in some cases, the pain may last for more than five years. Patients suffering from severe, prolonged pain endure significant distress, which seriously affects their quality of life and daily activities. Moreover, PHN can lead to insomnia, anxiety, depression, or even suicide. Currently, the treatment of PHN primarily focuses on pain management. First-line treatment options include gabapentin, pregabalin, tricyclic antidepressants, and 5% lidocaine patches.\n\nAcupuncture is a widely used non-pharmacological therapy. A large number of clinical trials have demonstrated its effectiveness in treating various neuropathic pain conditions, including PHN. Acupuncture not only reduces pain perception but also alleviates anxiety and improves the quality of life for PHN patients. Among different acupuncture techniques, Warm Acupuncture (WA) is considered the most effective for treating peripheral neuropathic pain. Clinical case reports have also shown its pain-relieving effects in PHN patients.\n\nHowever, there has been no study in Vietnam on the effectiveness of WA in pain reduction for patients with PHN. Therefore, this study is conducted to evaluate whether WA is effective in reducing pain and ensuring safety for treating PHN patients with Qi Stagnation and Blood Stasis syndrome. The findings will serve as a basis for the broader application of WA in the treatment of PHN.",[26],[109,55],"Warm acupuncture","2025-03-18",{"date":112,"type":31},"2025-03-25",{"date":114,"type":20},"2025-04-01",{"date":116,"type":20},"2025-08-29",{"name":118,"class":95},"University of Medicine and Pharmacy at Ho Chi Minh City"]